{
    "organizations": [],
    "uuid": "f9568f91f3095951dff55dd362feb0fb6ca64db9",
    "author": "",
    "url": "https://www.reuters.com/article/brief-novartis-enters-agreement-to-acqui/brief-novartis-enters-agreement-to-acquire-avexis-for-8-7-bln-idUSASO000317",
    "ord_in_thread": 0,
    "title": "BRIEF-Novartis Enters Agreement To Acquire AveXis For $8.7 Bln",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 9, 2018 / 4:54 AM / Updated 11 minutes ago BRIEF-Novartis Enters Agreement To Acquire AveXis For $8.7 Bln Reuters Staff 1 Min Read \nApril 9 (Reuters) - Novartis AG: \n* NOVARTIS ENTERS AGREEMENT TO ACQUIRE AVEXIS INC. FOR USD 8.7 BN TO TRANSFORM CARE IN SMA AND EXPAND POSITION AS A GENE THERAPY AND NEUROSCIENCE LEADER \n* NOVARTIS ENTERS AGREEMENT TO ACQUIRE AVEXIS INC. FOR USD 8.7 BN TO TRANSFORM CARE IN SMA AND EXPAND POSITION AS A GENE THERAPY AND NEUROSCIENCE LEADER \n* NOVARTIS AG- ‚ÄçASSUMING MID 2018 COMPLETION, ACQUISITION IMPACT WOULD BE SLIGHTLY NEGATIVE TO CORE OPERATING INCOME IN 2018 AND 2019 Source text for Eikon: Further company coverage:",
    "published": "2018-04-09T07:50:00.000+03:00",
    "crawled": "2018-04-09T08:11:35.018+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "updated",
        "minute",
        "ago",
        "enters",
        "agreement",
        "acquire",
        "avexis",
        "bln",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "novartis",
        "ag",
        "novartis",
        "enters",
        "agreement",
        "acquire",
        "avexis",
        "usd",
        "bn",
        "transform",
        "care",
        "sma",
        "expand",
        "position",
        "gene",
        "therapy",
        "neuroscience",
        "leader",
        "novartis",
        "enters",
        "agreement",
        "acquire",
        "avexis",
        "usd",
        "bn",
        "transform",
        "care",
        "sma",
        "expand",
        "position",
        "gene",
        "therapy",
        "neuroscience",
        "leader",
        "novartis",
        "mid",
        "completion",
        "acquisition",
        "impact",
        "would",
        "slightly",
        "negative",
        "core",
        "operating",
        "income",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}